Lifeboat Foundation

Similarly, the CNSA told the Chinese state-run news outlet Global Times that its Tianwen-1 space probe and Zhurong rover will pause their work and enter safe mode during the transit.

But just because the rovers aren’t getting any new instructions doesn’t mean they’re stopping altogether.

“Though our Mars missions won’t be as active these next few weeks, they’ll still let us know their state of health,” the NASA Jet Propulsion Laboratory’s Mars Relay Network manager, Roy Gladden, said in the NASA announcement. “Each mission has been given some homework to do until they hear from us again.”

Re-Imagining Health and Wellbeing — Lisa Esch & Dr. Michael Petersen, M.D., NTT.

The Nippon Telegraph and Telephone Corporation (https://hello.global.ntt/en-us/), commonly known as NTT, is a Japanese telecommunications company headquartered in Tokyo, Japan.

Continue reading “Lisa Esch & Dr. Michael Petersen, M.D. — NTT Data Services — Re-Imagining Health and Wellbeing” »

Getting a quick and accurate reading of an X-ray or some other medical images can be vital to a patient’s health and might even save a life. Obtaining such an assessment depends on the availability of a skilled radiologist and, consequently, a rapid response is not always possible. For that reason, says Ruizhi “Ray” Liao, a postdoc and a recent Ph.D. graduate at MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL), “we want to train machines that are capable of reproducing what radiologists do every day.” Liao is the first author of a new paper, written with other researchers at MIT and Boston-area hospitals, that is being presented this fall at MICCAI 2,021 an international conference on medical image computing.

Today, the World Health Organization (WHO) and partners launched the first ever global strategy to defeat meningitis — a debilitating disease that kills hundreds of thousands of people each year. By 2,030 the goals are to eliminate epidemics of bacterial meningitis – the most deadly form of the disease – and to reduce deaths by 70% and halve the number of cases. The organizations estimate that in total, the strategy could save more.

Than 200,000 lives annually and significantly reduce disability caused by the disease. This strategy, the Global Roadmap to Defeat Meningitis by 2,030 was launched by a broad coalition of partners involved in meningitis prevention and control at a virtual event, hosted by WHO in Geneva. Its focus is on preventing infections and improving.

Care and diagnosis for those affected.“Wherever it occurs, meningitis can be deadly and debilitating; it strikes quickly, has serious health, economic and social consequences, and causes devastating outbreaks,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.

SARS-CoV-2 remains a global threat to human health particularly as escape mutants emerge. There is an unmet need for effective treatments against COVID-19 for which neutralizing single domain antibodies (nanobodies) have significant potential. Their small size and stability mean that nanobodies are compatible with respiratory administration. We report four nanobodies (C5, H3, C1, F2) engineered as homotrimers with pmolar affinity for the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. Crystal structures show C5 and H3 overlap the ACE2 epitope, whilst C1 and F2 bind to a different epitope. Cryo Electron Microscopy shows C5 binding results in an all down arrangement of the Spike protein. C1, H3 and C5 all neutralize the Victoria strain, and the highly transmissible Alpha (B.1.1.7 first identified in Kent, UK) strain and C1 also neutralizes the Beta (B.1.35, first identified in South Africa). Administration of C5-trimer via the respiratory route showed potent therapeutic efficacy in the Syrian hamster model of COVID-19 and separately, effective prophylaxis. The molecule was similarly potent by intraperitoneal injection.

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat. Struct. Mol. Biol. 27 846–854 (2020).

Innovator, philanthropist, humanitarian — khaliya — discussing radical solutions for the global mental health crisis.

Khaliya (https://www.khaliya.net/) is a Columbia University-trained public health specialist and Harvard University-trained specialist in Global Mental Health and Refugee Trauma. She is also a Venture Partner for Gender Equity Diversity Investments (www.gedi.vc), a new female-led VC firm targeting high growth investments that deliver top-quartile returns and measurable impact towards the UN Sustainable Development Goals with a preliminary focus on health.

Continue reading “Khaliya — Innovator, Philanthropist, Humanitarian — Solutions For The Global Mental Health Crisis” »

As Australia turns to nuclear power for its submarines, a UK prototype will test the use of autonomous green hydrogen submarines for freight transport.

A world-first green submarine project will soon get underway after a proposal to power an autonomous underwater vessel with green hydrogen won a share of a United Kingdom £23 million funding program.

Start-up company Oceanways is to build a prototype of a zero emission submarine initially designed to deliver cargo in a twenty-foot container between Glasgow and Belfast.

Continue reading “Special delivery service: Green hydrogen submarines are on their way” »

This year’s deadline for applications is November 15 2021. To learn more, visit https://aws.amazon.com/health/health-equity.

AWS is announcing a new global program to support organizations working to enhance health outcomes for underserved or underrepresented communities. We are providing AWS credits and technical expertise, committing $40 million over three years to help organizations develop solutions to improve health outcomes.

A new computer model demonstrates that vaccinations have impacts well beyond just preventing disease and death: they can also slow the spread of antimicrobial resistance.

Pneumococcal diseases—which include illnesses ranging from inner ear infections to pneumonia and meningitis—are a leading cause of death globally among children under five. While there are effective vaccines against pneumococcal diseases, access is still a challenge for populations in low-income—and some middle income—countries. And antimicrobial resistance to the antibiotics commonly used to treat these infections is a growing problem.

“We wanted to model the value of vaccinating—not only to show that vaccination reduces death or disability from these diseases, but also to quantify whether vaccination can slow antimicrobial resistance,” says Andrew Stringer, an assistant professor of veterinary and global health at NC State.